CLDX - Company ID 0000744218
Celldex Therapeutics, Inc. (CLDX) reported revenue of $1.54M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $1.54M | -78.0% |
| FY 2024 | $7.02M | +2.0% |
| FY 2023 | $6.88M | +192.0% |
| FY 2022 | $2.36M | -49.3% |
| FY 2021 | $4.65M | -37.3% |
| FY 2020 | $7.42M | +107.6% |
| FY 2019 | $3.57M | -62.5% |
| FY 2018 | $9.54M | -25.2% |
| FY 2017 |
Celldex Therapeutics, Inc. (CLDX) reported revenue of $1.54M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, Celldex Therapeutics, Inc.'s revenue declined from $9.27M to $1.54M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $12.74M |
| +87.8% |
| FY 2016 | $6.79M | +23.8% |
| FY 2015 | $5.48M | +52.8% |
| FY 2014 | $3.59M | -12.8% |
| FY 2013 | $4.11M | -63.3% |
| FY 2012 | $11.20M | +20.9% |
| FY 2011 | $9.27M | - |